- Conditions
- Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis
- Interventions
- PDA001 (cenplacel-L)
- Biological
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Denver, Colorado • Cincinnati, Ohio + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 596
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension, Pulmonary, Lung Diseases, Interstitial
- Interventions
- Inhaled Nitric Oxide (iNO)
- Device
- Lead sponsor
- Third Pole Therapeutics, Inc.
- Industry
- Eligibility
- 22 Years to 84 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Cincinnati, Ohio • Charleston, South Carolina
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Common Variable Immunodeficiency, Interstitial Lung Disease Due to Systemic Disease
- Interventions
- Fisetin, Placebo
- Drug
- Lead sponsor
- Avni Joshi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Sarcoidosis
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
- Interventions
- L606 inhalation suspension
- Combination Product
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more
- Conditions
- Lung Diseases, Herpesvirus Infections
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Idiopathic Pulmonary Fibrosis, Hypoxemia
- Interventions
- GBT440
- Drug
- Lead sponsor
- Global Blood Therapeutics
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Denver, Colorado • New Orleans, Louisiana + 3 more
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
- Interventions
- Tipifarnib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Danbury, Connecticut • New Orleans, Louisiana • Minneapolis, Minnesota + 3 more
- Conditions
- Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
- Interventions
- Spirometer, Oximeter, Scale, ePROs (electronic patient reported outcomes)
- Device · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Interventions
- iNO
- Combination Product
- Lead sponsor
- Bellerophon
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
- Conditions
- Pulmonary Fibrosis, Lung Cancer
- Interventions
- [68Ga]CBP8, PET Imaging
- Drug · Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Matrix
- Biological
- Lead sponsor
- Maule Stem Cell Research Institute, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Venice, Florida
- Conditions
- Systemic Sclerosis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Arlington, Texas
- Conditions
- Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu's Arteritis, Henoch-Schoenlein Purpura, Behcet's Disease, CNS Vasculitis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 707 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pulmonary Fibrosis, Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- Mosliciguat, Placebo, Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Kissimmee, Florida • Louisville, Kentucky • Bend, Oregon
- Conditions
- Lung Cancer, Lung Metastases
- Interventions
- Nintedanib, Prednisone, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 12
- States / cities
- Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more
- Conditions
- Hypertension, Pulmonary, Lung Diseases, Interstitial
- Interventions
- TX000045
- Drug
- Lead sponsor
- Tectonic Operating Company, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • San Francisco, California • Idaho Falls, Idaho + 1 more
- Conditions
- Coal Workers' Pneumoconiosis (Complicated)
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- Pulmonary Research of Abingdon, LLC
- Other
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Abingdon, Virginia